Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

This study will evaluate efficacy and safety of anti-PD-1/PD-L1 antibodies combined with bevacizumab and metronomic cyclophosphamide in patients with metastatic non-small cell lung cancer (NSCLC) and cutaneous melanoma previously treated with immune checkpoint blockade (ICB). The hypotheses of this study are that a combination of ICB, cyclophosphamide, and bevacizumab prolongs progression-free survival and overall survival, and also increases rates of objective responses and disease control.

Trial Details

NCT ID
NCT07130032
Phase
PHASE2
Sponsor
EuroCityClinic LLC
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • reICB regimen (NSCLC)
  • reICB regimen (melanoma)
Locations (sample)
  • Saint Petersburg, Sankt-Peterburg, Russia|59.93863,30.31413

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Provide written informed consent
  • Age ≥ 18 years
  • Histologically confirmed diagnosis of NSCLC and cutaneous melanoma with distant metastases.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →